Search results for "Liver cirrhosis."

showing 10 items of 598 documents

Podoplanin discriminates distinct stromal cell populations and a novel progenitor subset in the liver

2015

Podoplanin/gp38+ stromal cells present in lymphoid organs play a central role in the formation and reorganization of the extracellular matrix and in the functional regulation of immune responses. Gp38+ cells are present during embryogenesis and in human livers of primary biliary cirrhosis. Since little is known about their function, we studied gp38+ cells during chronic liver inflammation in models of biliary and parenchymal liver fibrosis and steatohepatitis. Gp38+ cells were analyzed using flow cytometry and confocal microscopy, and the expression of their steady state and inflammation-associated genes was evaluated from healthy and inflamed livers. Gp38+ cells significantly expanded in …

Male0301 basic medicinePathologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BStromal cellPhysiologyLiver and Biliary Tract Physiology/PathophysiologyPopulationCell SeparationBiologyLiver Cirrhosis Experimental03 medical and health sciencesPrimary biliary cirrhosisAntigens CDNon-alcoholic Fatty Liver DiseasePhysiology (medical)medicineAnimalsAC133 AntigenProgenitor celleducationCells CulturedGlycoproteinsMice KnockoutLiver injuryeducation.field_of_studyMembrane GlycoproteinsMicroscopy ConfocalHepatologyLiver Cirrhosis BiliaryStem CellsLiver cellGastroenterologyFlow Cytometrymedicine.diseaseMolecular biologyMice Inbred C57BLPhenotype030104 developmental biologyGene Expression RegulationLiverChemical and Drug Induced Liver InjuryInflammation MediatorsStromal CellsStem cellSteatohepatitisPeptidesBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

2019

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAA…

Male0301 basic medicinemedicine.medical_specialtySurvival rateCarcinoma HepatocellularCirrhosisSustained Virologic ResponsePrognosiHepatitis C virus (HCV) Hepatocellular carcinoma (HCC) Direct-acting antiviral (DAA) Overall survival Prognosis Survival rate Liver cirrhosisHepacivirusAntiviral AgentsGastroenterologyLiver cirrhosi03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEarly Hepatocellular CarcinomaOverall survivalProspective StudiesHepatocellular carcinoma (HCC)Propensity ScoreSurvival rateAgedAged 80 and overHepatologybusiness.industryLiver NeoplasmsHazard ratioDirect-acting antiviral (DAA)Hepatitis CHepatitis C virus (HCV)Middle Agedmedicine.diseasePrognosisHepatitis CDirect-acting antiviral (DAA); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Survival rate030104 developmental biologyHepatocellular carcinomaLiver cirrhosisFemale030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessViral hepatitisFollow-Up Studies
researchProduct

Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

2022

Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 …

MaleCarcinoma HepatocellularCholestatic liver disease; Outcome; Surveillance; Survival; TreatmentSurveillanceHepatologySurvivalPrognosiLiver Cirrhosis BiliaryRisk FactorSettore MED/12 - GASTROENTEROLOGIALiver NeoplasmsGastroenterologyCholestatic liver diseasePrognosisTreatmentRisk FactorsHumansFemaleTreatment.HumanAgedOutcome
researchProduct

Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey

2016

The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Background The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Methods We enrolled 2,557 CLD consecutive patients in 16 Italian liver units in 2014. Results HBV etiology accounted for 513 (20.2%) cases, alone in 439 and associated with HCV and/or alcohol abuse in 74. Of these 513, 11.9% were anti-HDV-positive and 7.2% HBeAg-positive. HCV alone was responsible for 50.3% of CLD and with alcohol abuse for 5.9%. HCV RNA was detec…

MaleCirrhosisAlcohol abuseGastroenterology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseSurveys and QuestionnairesEpidemiologyOutpatients80 and overSurveys and QuestionnaireChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Adolescent; Adult; Aged; Aged 80 and over; Alcoholism; Carcinoma Hepatocellular; Female; Genotype; Hepatitis B; Hepatitis C; Humans; Inpatients; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Outpatients; Surveys and Questionnaires; Young Adult; Hepatology; Gastroenterology030212 general & internal medicineYoung adultHCCChronic liver diseasesChronic hepatitisAged 80 and overMedicine (all)Liver NeoplasmsChronic liver diseaseGastroenterologyvirus diseasesOutpatientHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver Neoplasm030211 gastroenterology & hepatologyFemaleInpatientHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentGenotypeLiver CirrhosiChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Medicine (all); Hepatology; Gastroenterology03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedInpatientsHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesLiver cirrhosisEtiologyChronic hepatitibusiness
researchProduct

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

2017

Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child…

MaleCirrhosisSettore MED/09 - Medicina InternaAlcohol abuseAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Internal Medicinemedicine.disease_causeGastroenterology0302 clinical medicineRisk FactorsEpidemiologyHBV030212 general & internal medicineLiver Neoplasmsvirus diseasesMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver NeoplasmHepatocellular carcinomaHCV030211 gastroenterology & hepatologyAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Aged; Alcoholism; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Internal MedicineFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusLiver CirrhosiAlcohol abuseLiver cirrhosis epidemiology03 medical and health sciencesInternal medicinemedicineInternal MedicineHumansDecompensationAgedHepatitis B virusCross-Sectional Studiebusiness.industryRisk FactorCarcinomaHepatocellularmedicine.diseaseCross-Sectional StudiesLiver cirrhosisEtiologybusiness
researchProduct

Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study

2020

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all p…

MaleCirrhosismedicine.medical_treatmentretrospective studylaparoscopyColonoscopymultimodal imagingComorbidityGastroenterologyprotionamide0302 clinical medicineLaparotomyAscitesamikacinMedicinebedaquilinePathologie maladies infectieusesintestine biopsyadultsteroidclinical trialGeneral MedicinerifabutinMicrobiologie et protistologie [entomologiephytoparasitolog.]priority journaldiabetes mellitushistopathologybiological productMicrobiology (medical)Microbiologie et protistologie [parasitologie hum. et anim.]medicine.medical_specialtyTuberculosis030106 microbiologymalignant neoplasmArticle03 medical and health scienceslaparotomyHuman immunodeficiency virus infectionmolecular diagnosisHumansTuberculosisGastro-intestinalhumanRetrospective Studiescolondisease predispositionmicrobiologyTuberculosis; Immune-suppression; Gastro-intestinal; Endoscopy;anusmedicine.diseasemajor clinical studymulticenter studyaminosalicylic acidcyclophosphamide0301 basic medicineBiopsyAntitubercular Agentsethambutolrifampicinterminal ileumcolonoscopyofloxacin030212 general & internal medicineLaparoscopyazathioprinemedicine.diagnostic_testIncidence (epidemiology)gastrointestinal tuberculosisDisease Managementchronic kidney failurecycloserineInfectious DiseasesfemaleTreatment OutcomeMolecular Diagnostic Techniquesdiagnostic testDisease Susceptibilitymedicine.symptommoxifloxacinSymptom AssessmentImmune-suppressionstomachisoniazidpyrazinamidestreptomycinliver cirrhosispatient referrallinezolidInternal medicineBiopsybusiness.industryEndoscopyMycobacterium tuberculosishuman tissueclinical featureTreatmentTuberculosis Gastrointestinaltuberculostatic agentbusinessMicrobiologie et protistologie [bacteriol.virolog.mycolog.]
researchProduct

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

2017

OBJECTIVES Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (F…

MaleLiver CirrhosisPathologyBiopsyPredictive Value of TestAspartate AminotransferasesGastroenterology0302 clinical medicineFibrosisReference ValuesNon-alcoholic Fatty Liver DiseaseArea under curvePrevalenceMedicineReference ValueAge FactorConfoundingAge FactorsGastroenterologyAlanine TransaminaseFalse Positive ReactionMiddle Aged3. Good healthLiver030220 oncology & carcinogenesisPredictive value of testsArea Under Curve030211 gastroenterology & hepatologyFemaleLiver pathologyHumanAdultmedicine.medical_specialtyLiver Cirrhosi610 Medicine & healthdigestive system03 medical and health sciencesPredictive Value of TestsInternal medicineHumansFalse Positive ReactionsAspartate AminotransferasesAgedHepatologybusiness.industryPlatelet CountNon invasivenutritional and metabolic diseasesAspartate AminotransferaseHepatologymedicine.diseaseFibrosisdigestive system diseasesFatty LiverROC CurveHuman medicinebusinessBiomarkersThe American Journal of Gastroenterology
researchProduct

Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting

2018

International audience; BACKGROUNDS & AIMS: Treating patients with decompensated cirrhosis with direct-acting antiviral (DAA) therapy while on the waiting list for liver transplantation results in substantial improvement of liver function allowing 1 in 4 patients to be removed from the waiting list or delisted, as reported in a previous study promoted by the European Liver and Intestine Transplant Association (ELITA). The aim of this study was to report on clinical outcomes of delisted patients, including mortality risk, hepatocellular carcinoma development and clinical decompensation requiring relisting. METHODS: One hundred and forty-two HCV-positive patients on the liver transplant waiti…

MaleLiver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularWaiting Listsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Liver transplantationSeverity of Illness IndexAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicineAscitesmedicineHumansDecompensationChronicdirect-acting antiviralsdirect-acting antiviralHepatologyliver transplantationbusiness.industrydelistingcirrhosisCarcinomaLiver NeoplasmsHepatocellularHepatitis CTransplant Waiting ListHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis C3. Good healthItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleLiver functionmedicine.symptombusinesscirrhosi
researchProduct

Mitochondrial biogenesis fails in secondary biliary cirrhosis in rats leading to mitochondrial DNA depletion and deletions

2011

Chronic cholestasis is characterizedby mitochondrial dysfunction, associated with loss of mitochondrialmembrane potential, decreased activities of respiratory chaincomplexes, and ATP production. Our aim was to determine themolecular mechanisms that link long-term cholestasis to mitochondrialdysfunction. We studied a model of chronic cholestasis inducedby bile duct ligation in rats. Key sensors and regulators of theenergetic state and mitochondrial biogenesis, mitochondrial DNA(mtDNA)-to-nuclear DNA (nDNA) ratio (mtDNA/nDNA) relativecopy number, mtDNA deletions, and indexes of apoptosis (BAX,BCL-2, and cleaved caspase 3) and cell proliferation (PCNA) wereevaluated. Our results show that long…

MaleMitochondrial DNAPhysiologyMitochondrial TurnoverMitochondrial HepatopathyNF-E2-Related Factor 1Respiratory chainMitochondria LiverProtein Serine-Threonine KinasesMitochondrionBiologyDNA MitochondrialSirtuin 1CholestasisProliferating Cell Nuclear AntigenPhysiology (medical)medicineAnimalsRats Wistarbcl-2-Associated X ProteinCholestasisHepatologyCaspase 3Liver Cirrhosis BiliaryGastroenterologyPyruvate Dehydrogenase Acetyl-Transferring KinaseRNA-Binding ProteinsTFAMmedicine.diseaseGA-Binding Protein Transcription FactorPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMolecular biologyRatsGenes MitochondrialProto-Oncogene Proteins c-bcl-2Mitochondrial biogenesisChronic DiseaseBile DuctsGene DeletionTranscription FactorsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is downregulated during cell growth and by transforming growt…

1992

Hepatocyte growth factor (HGF) has been detected in non-parenchymal cells but not in hepatocytes. We performed Northern blot analysis of total RNA extracted from rat hepatocytes, Kupffer cells, endothelial cells and fat-storing (Ito-) cells. Total RNA was extracted from fat-storing cells at different times after isolation and from cells treated with different amounts of transforming growth factor beta. The RNA was hybridized with HGF, fibronectin-, and alpha-actin-specific cDNA probes, consecutively. We found an abundant amount of HGF mRNA in freshly isolated fat-storing cells, but not in other liver cells. The amount of the HGF transcripts decreases significantly in FSC during the time of …

MaleMolecular Sequence DataBiophysicsDown-RegulationCell SeparationLiver Cirrhosis ExperimentalBiochemistryTransforming Growth Factor betaGene expressionmedicineAnimalsNorthern blotGrowth SubstancesMolecular BiologyCells CulturedMessenger RNABase SequencebiologyHepatocyte Growth FactorCell BiologyTransforming growth factor betaBlotting NorthernMolecular biologyActinsFibronectinsRatsBlotmedicine.anatomical_structureAdipose TissueGene Expression RegulationLiverHepatocytebiology.proteinHepatocyte growth factorDNA Probesmedicine.drugTransforming growth factorBiochemical and Biophysical Research Communications
researchProduct